[
  {
    "ts": null,
    "headline": "Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips",
    "summary": "HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.",
    "url": "https://finnhub.io/api/news?id=364cdf4d1dcf49988cbceca1d5cc6946a0bd251c195371392ab62f1abf704c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770388260,
      "headline": "Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips",
      "id": 138376946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.",
      "url": "https://finnhub.io/api/news?id=364cdf4d1dcf49988cbceca1d5cc6946a0bd251c195371392ab62f1abf704c69"
    }
  },
  {
    "ts": null,
    "headline": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "url": "https://finnhub.io/api/news?id=3507a3d67d7208b5f1044f8deac437c2f46c77ad4605acd398de7a75fc7b99c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770383735,
      "headline": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
      "id": 138375553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
      "url": "https://finnhub.io/api/news?id=3507a3d67d7208b5f1044f8deac437c2f46c77ad4605acd398de7a75fc7b99c5"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific price target lowered to $110 from $125 at Stifel",
    "summary": "Stifel lowered the firm’s price target on Boston Scientific (BSX) to $110 from $125 and keeps a Buy rating on the shares following the company’s quarterly report. Investors seem likely to wait for more visible signs of stability and a “what’s next” catalyst before “enthusiastically embracing the stock again,” the analyst contends.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and",
    "url": "https://finnhub.io/api/news?id=32646f819118e5ecd9b7734b408ca89ffa024c7379bfcded5659be9df34008b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770383283,
      "headline": "Boston Scientific price target lowered to $110 from $125 at Stifel",
      "id": 138374474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Stifel lowered the firm’s price target on Boston Scientific (BSX) to $110 from $125 and keeps a Buy rating on the shares following the company’s quarterly report. Investors seem likely to wait for more visible signs of stability and a “what’s next” catalyst before “enthusiastically embracing the stock again,” the analyst contends.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and",
      "url": "https://finnhub.io/api/news?id=32646f819118e5ecd9b7734b408ca89ffa024c7379bfcded5659be9df34008b7"
    }
  }
]